Lee Min A, Hwang Byoung Wook, Ha Sang Woo, Kim Jae Ho, Kim Hak Sung, Ahn Seong Hwan
Department of Neurology, School of Medicine, Chosun University, Gwangju, Korea.
Department of Neurosurgery, School of Medicine, Chosun University, Gwangju, Korea.
Neurointervention. 2023 Nov;18(3):159-165. doi: 10.5469/neuroint.2023.00353. Epub 2023 Oct 23.
Patients with minor stroke (National Institutes of Health Stroke Scale score ≤5) and large vessel occlusion (LVO) often experience neurological deterioration >24 hours after onset. However, the efficacy of endovascular reperfusion therapy in these patients remains unclear. The aim of this study was to determine the efficacy and safety of reperfusion therapy in patients with minor stroke and neurological deterioration >24 hours after onset.
Data were retrospectively reviewed from patients between January 2019 and April 2022 who met the following criteria: (1) minor stroke and small definitive ischemic lesions at initial visit, (2) onset to neurological deterioration >24 hours, (3) cortical signs, Alberta Stroke Program Early computed tomography (CT) Score >6 points, and large artery occlusion confirmed by CT angiography at neurological deterioration. Efficacy and safety outcomes were based on final thrombolysis in cerebral infarction (TICI), incidence of symptomatic intracranial hemorrhage (ICH), and mortality. Outcomes were assessed using the modified Rankin Scale (mRS) at 3 months. Good outcome was defined as a mRS of 0, 1, or 2.
Data from 26 patients (38.4% female, mean age 75.8 years) were analyzed; 18 (69.2%) had a good outcome. A final TICI of 2b or 3 was observed in 24 (92.3%) patients. No other adverse events, including dissection, vasospasm or distal embolization, were observed during the procedures. Hemorrhagic events occurred in 8 patients after the procedure; however, there were no symptomatic ICHs. Good prognostic factors were younger age (P=0.062) and carotid stenting (P=0.025).
Endovascular reperfusion therapy performed in selected patients with minor stroke, LVO, and neurological deterioration >24 hours after stroke onset demonstrated favorable outcomes and safety.
轻度卒中(美国国立卫生研究院卒中量表评分≤5分)且存在大血管闭塞(LVO)的患者常在发病24小时后出现神经功能恶化。然而,这些患者接受血管内再灌注治疗的疗效仍不明确。本研究的目的是确定在发病24小时后出现神经功能恶化的轻度卒中患者中再灌注治疗的疗效和安全性。
回顾性分析2019年1月至2022年4月期间符合以下标准的患者数据:(1)初诊时为轻度卒中和明确的小缺血性病灶,(2)发病至神经功能恶化>24小时,(3)有皮质体征,阿尔伯塔卒中项目早期计算机断层扫描(CT)评分>6分,且在神经功能恶化时经CT血管造影证实为大动脉闭塞。疗效和安全性结局基于脑梗死最终溶栓(TICI)、症状性颅内出血(ICH)发生率和死亡率。在3个月时使用改良Rankin量表(mRS)评估结局。良好结局定义为mRS为0、1或2。
分析了26例患者的数据(女性占38.4%;平均年龄75.8岁);18例(69.2%)获得良好结局。24例(92.3%)患者的最终TICI为2b或3。在操作过程中未观察到其他不良事件,包括夹层、血管痉挛或远端栓塞。术后有8例患者发生出血事件;然而,没有症状性ICH。良好的预后因素为年龄较轻(P=0.062)和颈动脉支架置入术(P=0.025)。
在选定的轻度卒中、LVO且卒中发病24小时后出现神经功能恶化的患者中进行血管内再灌注治疗显示出良好的结局和安全性。